drugset / Trial / NCT07635394

Efficacy of Pregabalin for Patients With Irritable Bowel Syndrome

NCT07635394

RandomizedParallel-groupOpen-labelTreatment

Summary

To explore the efficacy of pregabalin for patients with irritable bowel syndrome (IBS).

Timeline

Start
2026-04-07
Primary completion
2026-04-08
Completion
2029-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 225 mg
Background Dicyclomine Small molecule
Background Eluxadoline Small molecule 75 mg
Background Eluxadoline Small molecule 100 mg
Background Hyoscyamine Small molecule
Background Loperamide Small molecule
Background Rifaximin Other / unclassified 550 mg